<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269566</url>
  </required_header>
  <id_info>
    <org_study_id>20140101480</org_study_id>
    <nct_id>NCT02269566</nct_id>
  </id_info>
  <brief_title>Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients</brief_title>
  <acronym>ILIT</acronym>
  <official_title>A Double-blinded Placebo-controlled Randomized Clinical Trial Evaluating the Efficacy and Adverse Effect of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thermo Fisher Scientific</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will perform double-blinded placebo-controlled randomized clinical trial which evaluates
      the efficacy and safety of allergen-specific intralymphatic immunotherapy (ILIT) for
      allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), cat,
      and dog that are sensitized and provoke rhinitis-related symptoms in patients with allergic
      rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent, subjects will be randomly assigned to ILIT group or placebo group in
      double-blind manner. In both group, causal allergen or placebo will be injected into inguinal
      lymph node through guidance by ultrasonography three times with 4-week interval. In ILIT
      group, initial dose of allergen will be 1,000-fold diluted solution from maximal
      concentration of allergen extract for subcutaneous immunotherapy (30 AU/ml for Df or Dp, 10
      AU/ml for Cat hair, and 1:1/10 weight/volume for dog hair/dander, HollisterStier, New
      Orleans, USA) in volume of 0.1ml. If skin is highly reactive in skin prick test, the initial
      dose will be 10-fold dilution from maximal concentration where diameter of wheal is less than
      that of histamine. After the first dose, allergen concentration will be escalated 3-fold at
      second dose, and 10-fold at third dose if there are no local or systemic hypersensitivity
      reaction. The allergen concentration will not change at second or third dose if there is mild
      local or systemic reaction. The allergen concentration will decrease by 10 or 100-fold from
      previous concentration or further injection will be holded if there is severe local or
      systemic reaction after sufficient explanation and discussion with subjects.

      The investigators will evaluate allergic rhinitis symptom score before and 4, 12 months after
      the initial treatment. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and
      Sino-Nasal Outcome Test (SNOT-20) will be used. Visual analogue scale (VAS) of symptoms
      including rhinorrhea, sneezing, nasal obstruction, postnasal drip, eye/nose/ear/palate
      itching, dyspnea, wheezing, chest discomfort as well as urticaria, angioedema, and itching on
      exposed skin during exposure to causal allergen in daily life will be also evaluated. Skin
      prick test, intradermal test, blood sampling for serum allergen-specific IgE, exhaled nitric
      oxide, and nasal lavage for Th1, Th2, and Treg cytokines will be also performed before and 4,
      12 months after the initial treatment.

      Adverse events will be recorded and graded according to Muller classification and Ring and
      Messner classification.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The number of enrolled subjects did not meet the goal during the study
  </why_stopped>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rhinoconjunctivitis Quality of Life Questionnaire</measure>
    <time_frame>up to 12 months after the initial treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNOT-20</measure>
    <time_frame>before and 4, 12 months after the initial treatment</time_frame>
    <description>Sino-Nasal Outcome Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin reactivity</measure>
    <time_frame>before and 4, 12 months after the initial treatment</time_frame>
    <description>Diameters of wheal provoked by causal allergens in skin prick test and intradermal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alllergen-specific IgE level</measure>
    <time_frame>before and 4, 12 months after the initial treatment</time_frame>
    <description>Serum alllergen-specific IgE level using UNICAP, Thermofisher Scientific, Sweden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal reactivity</measure>
    <time_frame>before and 4, 12 months after the initial treatment</time_frame>
    <description>Threshold concentration in nasal provocation test for allergens of Df and Dp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines in nasal lavage fluid</measure>
    <time_frame>before and 4, 12 months after the initial treatment</time_frame>
    <description>Cytokines of Th1, Th2, and Treg in nasal lavage fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled NO</measure>
    <time_frame>before and 4, 12 months after the initial treatment</time_frame>
    <description>Exhaled nitric oxide measuring NIOX MINO, Thermofisher Scientific, Sweden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergic rhinitis symptoms during allergen exposure in daily life</measure>
    <time_frame>before and 4, 12 months after the initial treatment</time_frame>
    <description>Visual analog scare of allergic rhinitis symptoms during allergen exposure in daily life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Allergen extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 ml of allergen extracts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline, 0.1 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HollisterStier</intervention_name>
    <description>0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node</description>
    <arm_group_label>Allergen extract</arm_group_label>
    <other_name>Allergen extracts, New Orleans, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>0.1 ml of normal saline 3 injections into an inguinal lymph node</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>JW-pharma, Seoul, Republic of Korea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allergic rhinitis to house dust mite (Df, Dp), cat or dog

          -  More than 3mm reaction at skin prick test for Df, Dp, cat or dog or more than class 3
             at serum specific IgE level (UNICAP or MAST)

        Exclusion Criteria:

          -  Uncontrolled or severe asthma according to Global Initiative of Asthma (GINA)
             guideline

          -  FEV1 less than 50% of predicted value if there is comorbid asthma.

          -  Subject rejects the enrollment into study

          -  Low compliance

          -  Pregnancy or lactation

          -  Significant cardiovascular, hepatic, renal, hematologic, oncologic, or infectious
             diseases

          -  Administration of beta blocker, angiotensin converting enzyme inhibitor, tricyclic
             antidepressant, immnosuppressant including systemic glucocorticosteroid (20mg or more
             dose of prednisolone or equivalent dose of other steroid) within last 2 weeks

          -  Prior history of allergen-specific immunotherapy

          -  Allergic rhinitis caused by other perennial or seasonal allergen

          -  Vulnerable volunteer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Min Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wüthrich B, Crameri R, Graf N, Johansen P, Kündig TM. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17908-12. doi: 10.1073/pnas.0803725105. Epub 2008 Nov 10.</citation>
    <PMID>19001265</PMID>
  </reference>
  <reference>
    <citation>Martínez-Gómez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kündig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009;150(1):59-65. doi: 10.1159/000210381. Epub 2009 Apr 2.</citation>
    <PMID>19339803</PMID>
  </reference>
  <reference>
    <citation>Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):537-43. doi: 10.1097/ACI.0b013e3283310ff7. Review.</citation>
    <PMID>19680119</PMID>
  </reference>
  <reference>
    <citation>von Moos S, Kündig TM, Senti G. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin North Am. 2011 May;31(2):391-406, xi. doi: 10.1016/j.iac.2011.02.012. Review.</citation>
    <PMID>21530827</PMID>
  </reference>
  <reference>
    <citation>Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, Steiner M, Hothorn LA, Grönlund H, Tivig C, Zaleska A, Soyer O, van Hage M, Akdis CA, Akdis M, Rose H, Kündig TM. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012 May;129(5):1290-6. doi: 10.1016/j.jaci.2012.02.026. Epub 2012 Mar 30.</citation>
    <PMID>22464647</PMID>
  </reference>
  <reference>
    <citation>Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013 Feb;131(2):412-20. doi: 10.1016/j.jaci.2012.10.056.</citation>
    <PMID>23374268</PMID>
  </reference>
  <reference>
    <citation>Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013 Nov;132(5):1248-1252.e5. doi: 10.1016/j.jaci.2013.07.033. Epub 2013 Sep 13.</citation>
    <PMID>24035151</PMID>
  </reference>
  <reference>
    <citation>Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014 Mar;133(3):930-1. doi: 10.1016/j.jaci.2013.11.036. Epub 2014 Jan 15.</citation>
    <PMID>24439076</PMID>
  </reference>
  <reference>
    <citation>Zaleska A, Eiwegger T, Soyer O, van de Veen W, Rhyner C, Soyka MB, Bekpen C, Demiröz D, Treis A, Söllner S, Palomares O, Kwok WW, Rose H, Senti G, Kündig TM, Ozoren N, Jutel M, Akdis CA, Crameri R, Akdis M. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy. 2014 Sep;69(9):1162-70. doi: 10.1111/all.12461. Epub 2014 Jul 12. Erratum in: Allergy. 2016 Jan;71(1):129.</citation>
    <PMID>24934402</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Sang Min Lee</investigator_full_name>
    <investigator_title>Assistant professor of Division of Pulmonology and Allergy</investigator_title>
  </responsible_party>
  <keyword>allergic rhinitis</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

